Skip to main content
Equibles
ADPT logo

ADPT · Adaptive Biotechnologies Corp · Metrics

Track ADPT — free

Use ADPT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ADPT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$24.57 -0.76 (-3.00%)
Russell 2000 member Rebalance outlook locked
Market Cap
$4.06B
Shares
159.60M
Volume · Oct 22 164.71K Avg daily vol (3M) 2.27M

ADPT metrics

78 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$25.33
Market cap
$4.06B

Price action

20 metrics
Price change (1W)
-1.1%
Price change (30D)
-9.7%
Price change (3M)
+15.4%
Price change (6M)
+78.4%
Price change (YTD)
+56.0%
Price change (1Y)
+46.0%
Trailing year
Price change (5Y)
-25.3%
52-week high
$29.84
52-week low
$12.41
Change from 52-week high
-15.1%
Change from 52-week low
+104.1%
Annualized volatility
66.7%
Annualized volatility (3M)
51.2%
Beta
1.7
RSI (14D)
45.8
Price vs SMA 50
-3.1%
Price vs SMA 200
+31.5%
Avg volume (3M)
2.27M
Relative volume
0.8
Average dollar volume
$58.11M

Company

3 metrics
Sector
Healthcare
Industry
Diagnostics & Research
Shares outstanding
159.60M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
12.6×
reciprocal yield 7.9%
EV / EBITDA
—
EV / EBIT
—
P / sales
13.2×
reciprocal yield 7.6%
P / book
28.4
reciprocal yield 3.5%
FCF yield
-0.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
6.9×
reciprocal yield 14.6%
EV / revenue historical average (5Y)
10.7×
reciprocal yield 9.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-29

Profitability

9 metrics
Gross margin
75.6%
Operating margin
-12.2%
Trailing 12 months
Net margin
-20.7%
Gross profit (TTM)
$232.83M
Operating profit (TTM)
−$37.46M
Net income (TTM)
−$63.85M
Trailing 12 months
Diluted EPS (TTM)
$-0.40
FCF margin
-7.8%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.42

Growth

11 metrics
Revenue growth YoY
+21.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$308.08M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+5.1%
Year over year · more shares
Revenue CAGR (3Y)
+14.3%
Revenue CAGR (5Y)
+23.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-44.7%
Return on assets
-10.0%
Debt / equity
0.0
Current ratio
4.8
EBITDA (TTM)
−$31.62M
Free cash flow (TTM)
−$24.03M
Quick ratio
4.7
Interest coverage
-3.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$169.87M
Latest balance sheet
Cash & equivalents
$169.87M
Total assets
$640.68M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$21.01M
Capital expenditures (TTM)
$3.02M
R&D (TTM)
$88.21M
SG&A (TTM)
—
Stock compensation (TTM)
$49.02M
R&D / revenue
28.6%
Stock compensation / revenue
15.9%

Ownership (13F)

9 metrics
13F filers
302
13F filer change QoQ
+4
Institutional ownership
101.9%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
47.7%
Private-fund adviser ownership
42.5%
Active holders' share change QoQ
+1.0%
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
15.0%

Short interest

3 metrics
Short interest
7.4%
Latest settlement · 4.4 days to cover
Days to cover
4.4d
Short-squeeze score
57 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$28.00M
Insider-sentiment score
6 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1478320 CUSIP 00650F109 13F (30d) 36 filings 36 filers Visit website Investor relations